Navigation Links
Quark Pharmaceuticals Announces Data Indicating Potential Utility of QPI-1007 for Treatment of Glaucoma
Date:7/27/2009

iRNAs and all of our pipeline candidates have exhibited optimal activity and stability while attenuating potential off-target effects."

Prof. Di Polo commented, "In patients with glaucoma, characteristic visual field changes and vision loss are caused by the death of retinal ganglion cells. While existing therapeutics are capable of reducing IOP, none act as selective neuroprotective agents. We are encouraged by the QPI-1007 data, which suggest a neuroprotective effect on retinal ganglion cells in experimental glaucoma, presenting a major breakthrough in novel treatments for this neurodegenerative disease."

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to other target tissues including the eye, ear, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified siRNA designed to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-4523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiovascular surgery and the prophylaxis of delayed graft function after kidney transplantation

Quark has a broad pipeline of siRNA drug candidates based on novel structures developed internally and is utilizing the chemistry
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Quark Pharmaceuticals Receives FDA Approval of IND for Kidney Transplant siRNA Drug DGFi
2. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
3. Quark Pharmaceuticals Presents Data on Synthetic siRNAs for Prevention of Ocular and Inner Ear Sensory Cell Damage
4. Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit
5. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
10. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... study led by researchers at The University of Texas ... to show remarkable promise for the treatment of relapsed ... recent interim findings of the 18-center Phase 2 study ... of Medicine . Previous interim findings were presented in ... Annual Meeting and Exposition. , Unprecedented results, ...
(Date:6/19/2013)... In a study published in the June 19 online ... team led by researchers from the University of California, ... cellular events that take place when cardiac regeneration occurs ... provide evidence that various cell lines in the heart ... cell types, than previously thought. , More importantly, the ...
(Date:6/19/2013)... A new understanding of the genetic process that ... of potentially dangerous lesions for some women, and also ... therapies in certain cases suggesting they could actually ... The analysis provides a clearer picture of the chromosomal ... papillomavirus sometimes leads to chronic infection and, in less ...
(Date:6/19/2013)... Iowa study reveals significant disparities between minority and ... abuse treatment programs. Moreover, these disparities vary widely ... suggest that for most states there,s something amiss," ... and biostatistics. "There are strong racial and ethnic ... substance abuse treatment programs successfully, and those disparities ...
(Date:6/19/2013)... 19, 2013) In early April, senior leaders from ... Hartford, Connecticut, to discuss one question: how can first ... , The preliminary results of this discussion are ... Events: The Hartford Consensus ," a concept paper published ... Journal of Trauma and Acute Care Surgery , ...
Breaking Medicine News(10 mins):Health News:Ibrutinib continues strong showing against mantle cell lymphoma 2Health News:Fate of the heart: Researchers track cellular events leading to cardiac regeneration 2Health News:Genetics of cervical cancer raise concern about antiviral therapy in some cases 2Health News:States vary widely on success rates for minorities in drug treatment programs 2Health News:States vary widely on success rates for minorities in drug treatment programs 3Health News:Hartford consensus aims to improve survival after mass shootings 2
... , His Longevity with the Deadly Disease Inspires ... Sept. 4 When Jerry Lewis takes the stage again on Labor Day ... the same lung disease as he will be watching - and not just ... from the funny man who suffers from a not-so-funny and little known fatal ...
... following is the Labor Day message of Stuart Appelbaum. Appelbaum is president of ... www.rwdsu.org , , NEW YORK, Sept. 4 ... the worst of times and the best of times. , , ... and incompetence our country is now in the midst of its greatest economic ...
... SHENZHEN, China, Sept. 4 /PRNewswire-FirstCall/ - Hard to ... its China based subsidiary Mellow Hope, has just ... Hydrolysate for Injection (Brand name: NUTRIPROTEIN) in India. ... for the brain. It helps CNS in multiple ...
... social exclusion, have health problems, study suggests, , FRIDAY, ... considered a depressant, teetotalers as well as heavy drinkers ... than moderate tipplers, a new study has found. , ... don,t drink report having fewer friends than drinkers do, ...
... ... Chain Drug Stores (NACDS) President and Chief Executive Officer Steven C. Anderson, IOM, CAE ... First Circuit ruling on September 3, 2009, upholding the reduction of average wholesale prices ... Alexandria, ...
... SHENYANG, China, Sept. 4 /PRNewswire-Asia/ -- ... wholly-owned subsidiary of China,s,leading IT solutions & services ... its development strategy and new products,officially launching three ... 16 multi-slice CT scanner, Sparkler 1.5T superconductive MRI, ...
Cached Medicine News:Health News:The Show Goes on for Pulmonary Fibrosis Patient Jerry Lewis 2Health News:The Show Goes on for Pulmonary Fibrosis Patient Jerry Lewis 3Health News:Stand Up for Health Care! A Labor Day Message From RWDSU President Stuart Appelbaum 2Health News:Stand Up for Health Care! A Labor Day Message From RWDSU President Stuart Appelbaum 3Health News:Hard To Treat Diseases (HTDS) Completes Injection Clinical Trial 2Health News:Hard To Treat Diseases (HTDS) Completes Injection Clinical Trial 3Health News:Non-Drinkers More Likely to Be Anxious, Depressed 2Health News:NACDS: Court Ruling on AWPs Shifts "Urgency for Action" to States 2Health News:Neusoft Announces New Releases of Flagship Medical Products 2
(Date:6/19/2013)... , June 19, 2013   Voices Against ... finding a cure for brain cancer, today announced that ... grant to support the clinical investigation of Toca 511 ... high grade glioma brain cancer (Grade 3 or Grade ... novel treatments for advanced cancer, with an initial focus ...
(Date:6/19/2013)... BETHESDA, Md. , June 19, 2013 /PRNewswire/ -- ... "Company"), an American healthcare company providing services in ... of United Family Healthcare, a network of private ... official opening of its Beijing United Family Rehabilitation ... development projects of the United Family Healthcare ("UFH") ...
(Date:6/19/2013)... -- BD Biosciences, a segment of BD (Becton, Dickinson and ... technology company, today announced the launch of the BD ... of high-performance research flow cytometers. The BD ... most compact footprint in its class at just 30" x ... (76.2 cm). Recognizing that space is a valuable commodity in ...
Breaking Medicine Technology:Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 2Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer 3Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 2Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 3Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 4Chindex International, Inc. Announces Opening of Beijing United Family Rehabilitation Hospital 5New BD Biosciences Flow Cytometry Cell Analyzer Enables Complex Multicolor Experiments in Disease Research 2
... DENVER, Nov. 12 Corgenix Medical Corporation (OTC Bulletin Board: ... today reported sales of $2,044,967 for the first fiscal quarter ... ended September 30, 2008, an increase of 2.2%. , The ... compared with an operating loss of $94,133 for the first ...
... WASHINGTON, Nov. 12 Women,s Health Weekly recently ... are working on nearly 1,000 life-changing medicines for diseases affecting ... the Pharmaceutical Research and Manufacturers of America ... Food and Drug Administration or are in human clinical trials. ...
Cached Medicine Technology:Corgenix Reports Financial Results for First Quarter of Fiscal 2010 2Corgenix Reports Financial Results for First Quarter of Fiscal 2010 3Record Number of New Medicines in Development for Women 2
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
... Finnpipette Focus from Thermo Labsystems ... ergonomics with uncompromising performance. ... offers a custom fit for ... shorter tip cones allow easier ...
... A fixed pipette is ... a single volume. Fixed volume ... and advantages as other Finnpipette ... design, Super blow-out (1-40ul), Soft-touch ...
... the borders of stereomicroscopy with increase ... high-contrast images and significantly more image ... resolution and contrast. The innovative operating ... all essential functions of a stereomicroscope ...
Medicine Products: